Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

U.S. Patent expirations for Cymbalta and Evista impact results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly

3Q Revenues: $4.9 billion (-16%)

3Q Earnings: $500.6 million (-58%)

YTD Revenues: $14.5 billion (-16%) 

YTD Earnings: $2.0 billion (-50%)

Comments: Results in the quarter were impacted by U.S. patent expirations for Cymbalta (-73% to $368.0 million) and Evista (-65% to $89.5 million), partially offset by volume growth other products. Humalog sales increased 15% to $706.1 million. Cialis sales increased 8% to $568.4 million. Humulin sales increased 9% to $335.9 million. Forteo sales were $332.2 million, up 8%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters